Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 4;3(3):111-121.
doi: 10.1002/jin2.48. eCollection 2018 Sep.

Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections

Lai Jiang  1 , Jia Lin  2 , Clifford C Taggart  1 , José A Bengoechea  1 , Christopher J Scott  3
Affiliations
Review

Nanodelivery strategies for the treatment of multidrug-resistant bacterial infections

Lai Jiang et al. J Interdiscip Nanomed. .

Abstract

One of the most important health concerns in society is the development of nosocomial infections caused by multidrug-resistant pathogens. The purpose of this review is to discuss the issues in current antibiotic therapies and the ongoing progress of developing new strategies for the treatment of ESKAPE pathogen infections, which is acronymized for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species. We not only examine the current issues caused by multidrug resistance but we also examine the barrier effects such as biofilm and intracellular localization exploited by these pathogens to avoid antibiotic exposure. Recent innovations in nanomedicine approaches and antibody antibiotic conjugates are reviewed as potential novel approaches for the treatment of bacterial infection, which ultimately may expand the useful life span of current antibiotics.

Keywords: Antibiotics; ESKAPE; infection; intracellular; nanoparticles.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A. Model of antibody antibiotic conjugate (AAC). The AAC consists of an anti‐S. aureus antibody covalently linked via the introduced cysteines to an antibiotic using a cathepsin‐cleavable linker containing a novel quaternary ammonium salt. B. Mechanism of AAC action. When AAC opsonized bacteria are taken up by host cells, intracellular proteases cleave the linker and readily release the antibiotic in its active form to kill S. aureus.
See this image and copyright information in PMC

References

    1. Abbo, A. , Navon‐Venezia, S. , Hammer‐Muntz, O. , Krichali, T. , Siegman‐Igra, Y. , and Carmeli, Y. 2005. Multidrug‐resistant Acinetobacter baumannii . Emerg. Infect. Dis. 11(1):22–29. - PMC - PubMed
    1. Abdelghany, S. M. , Quinn, D. J. , Ingram, R. J. , Gilmore, B. F. , Donnelly, R. F. , Taggart, C. C. , and Scott, C. J. 2012. Gentamicin‐loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection. Int. J. Nanomedicine 7:4053–4063. - PMC - PubMed
    1. Al Mobarak, M. F. et al. 2014. Antimicrobial resistance patterns among Acinetobacter baumannii isolated from King Abdulaziz Hospital, Jeddah, Saudi Arabia, four‐year surveillance study (2010–2013). Egyptian Journal of Medical Microbiology. 23(4):53–60.
    1. Alhajlan, M. , Alhariri, M. , and Omri, A. 2013. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob. Agents Chemother. 57(6):2694–2704. - PMC - PubMed
    1. Bains, B. K. , Greene, M. K. , McGirr, L. M. , Dorman, J. , Farrow, S. N. , and Scott, C. J. 2016. Encapsulation of the p38 MAPK inhibitor GSK 678361A in nanoparticles for inflammatory‐based disease states. Journal of Interdisciplinary Nanomedicine. 1(3):85–92.

LinkOut - more resources